Atomwise Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Employees
  • 55
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $123M
Latest Deal Amount
  • Investors
  • 26

Atomwise General Information

Description

Operator of an artificial intelligence-based biotechnology company intended to help invent new potential medicines for more than 50 disease targets. The company's technology helps in drug hit discovery, binding affinity prediction and toxicity detection, enabling scientists to discover small molecules for the treatment and investigation of human diseases.

Contact Information

Formerly Known As
Chematria
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 717 Market Street
  • Suite 800
  • San Francisco, CA 94103
  • United States

Atomwise Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Atomwise Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC (Series B) 11-Aug-2020 $123M 00000 00000 Completed Generating Revenue
9. Later Stage VC (Series A) 02-Jul-2018 0000 000.00 00000 Completed Generating Revenue
8. Accelerator/Incubator 01-Jan-2016 00.000 Completed Generating Revenue
7. Seed Round 05-May-2015 000 00.000 Completed Generating Revenue
6. Accelerator/Incubator 24-Mar-2015 00000 00000 00.000 Completed Generating Revenue
5. Seed Round 01-Mar-2015 00000 00000 Completed Generating Revenue
4. Angel (individual) Completed Startup
3. Grant 01-Jan-2013 00000 Completed Startup
2. Accelerator/Incubator Completed Startup
1. Accelerator/Incubator Completed Startup
To view Atomwise’s complete valuation and funding history, request access »

Atomwise Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A-8 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A-7 00,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A-6 000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A-5 000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A-4 00,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A-3 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A-2 159,056 $0.000010 8% $0.27 $0.27 1x $0.27 0.34%
Series A-1 9,016,169 $0.000010 8% $4.99 $4.99 1x $4.99 19.21%
To view Atomwise’s complete cap table history, request access »

Atomwise Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of an artificial intelligence-based biotechnology company intended to help invent new potential medicines for m
Drug Discovery
San Francisco, CA
55 As of 2020
00000
0000 0000-00-00
00000000000 00000

00 00000

aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea com
0000 000000000
Guilford, CT
00 As of 0000
0000
000000000 - 0000

0000000

magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex
0000000000000
Toronto, Canada
00 As of 0000
000.00
00000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Atomwise Competitors (29)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AI Therapeutics Venture Capital-Backed Guilford, CT 00 0000 000000000 - 0000
0000000 Venture Capital-Backed Toronto, Canada 00 000.00 00000 000.00
000000000000 Private Equity-Backed London, United Kingdom 000 00000 0000000 0000 00000
000000000 00000000 Venture Capital-Backed Salt Lake City, UT 000 00000 00000000000 00000
0000000000 0000000 Venture Capital-Backed Brighton, United Kingdom 0 000.00 0000000000 0 000.00
You’re viewing 5 of 29 competitors. Get the full list »

Atomwise Executive Team (4)

Name Title Board Seat Contact Info
Abraham Heifets Ph.D Co-Founder & Chief Executive Officer
Izhar Wallach Ph.D Co-Founder & Chief Technology Officer
Han Lim Chief Business Officer
To view Atomwise’s complete executive team members history, request access »

Atomwise Board Members (6)

Name Representing Role Since
Adam Seabrook B Capital Group Board Observer 000 0000
Gavin Teo B Capital Group Board Member 000 0000
Hani Enaya Ph.D Sanabil Investments Board Observer 000 0000
Matthew Ocko Data Collective Board Member 000 0000
Raj Ganguly B Capital Group Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Atomwise Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Atomwise Investors (26)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
DCVC Bio Venture Capital Minority 000 0000 000000 0
Sanabil Investments Asset Manager Minority 000 0000 000000 0
AimTop Ventures Venture Capital Minority 000 0000 000000 0
Baidu Ventures Corporate Venture Capital Minority 000 0000 000000 0
B Capital Group Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 26 investors. Get the full list »

Atomwise Investments (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 0000000 (000 03-Dec-2019 00000 0000000 Drug Discovery 0000000 0000000 00.0
00000000 & 0000000 11-Sep-2019 00000 0000000 Drug Discovery 0000000 0000000 00.0
00000000 & 0000000 10-Sep-2019 00000 0000000 Biotechnology 0000000 0000000 00.0
Joint Venture - (SEngine Precision Medicine/Atomwise) 10-Sep-2019 Joint Venture Biotechnology 0000000 0000000 00.0
To view Atomwise’s complete investments history, request access »